IPO - Processa Pharmaceuticals, Inc.

Form Type: 424B4

Filing Date: 2025-06-18

Corporate Action: Ipo

Type: New

Accession Number: 000164117225015507

Filing Summary: Processa Pharmaceuticals, Inc. is conducting a public offering of 14,310,000 shares of common stock at a price of $0.25 per share, alongside 13,690,000 pre-funded warrants and 28,000,000 common warrants, which are immediately exercisable. Each pre-funded warrant has an exercise price of $0.0001 per share and will expire when fully exercised. The public offering will allow investors to beneficially own up to 9.99% of common stock. The placement agent for this offering, H.C. Wainwright & Co., will receive placement fees, and the estimated proceeds from the offering, expected to close on June 18, 2025, is approximately $6.2 million after deducting fees and expenses. The company aims to utilize the proceeds for continuing clinical trials and general corporate purposes, and there is no minimum offering requirement, meaning it may proceed with the sale of fewer than all shares, potentially impacting business plans. Processa is categorized as a ‘smaller reporting company’ under federal securities laws, allowing for reduced reporting obligations. The company has relied on third-party research to support its market assessment but emphasizes the risks associated with its growth trajectory and need for future capital raises.

Form Type: S-1

Filing Date: 2025-06-13

Corporate Action: Ipo

Type: New

Accession Number: 000164117225014967

Filing Summary: Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has filed a Form S-1 registration statement with the SEC on June 13, 2025, to offer up to 20,588,235 shares of common stock at an assumed public offering price of $0.34 per share, alongside Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants. The offering aims to raise funds to support ongoing Phase 2 clinical trials for its Next Generation Cancer therapies and general corporate purposes while highlighting a potential net proceeds of approximately $6.3 million after deducting fees. The company emphasizes its smaller reporting company status under federal securities law, allowing for certain scaled disclosures. This offering is planned to terminate on June 25, 2025, unless an earlier termination occurs at the company’s discretion. Potential investors are cautioned about the associated risks and should consider all risk factors before investing. The common stock is to be traded on The Nasdaq under the symbol “PCSA.”

Form Type: DRS

Filing Date: 2025-05-01

Corporate Action: Ipo

Type: New

Accession Number: 000164117225008061

Filing Summary: On May 1, 2025, Processa Pharmaceuticals, Inc. confidentially submitted a draft registration statement with the SEC for an initial public offering (IPO). The company is a clinical-stage biopharmaceutical entity focusing on developing Next Generation Cancer therapies. They are working on a pipeline of small molecule therapies, with two in or completed Phase 2 trials, indicating promising clinical development. The offering includes shares of common stock, pre-funded warrants, and common warrants. The company does not have a minimum offering amount for the closing; thus, it may sell fewer securities than proposed. There are potential risks associated with this offering, including a high degree of uncertainty regarding the future performance of the company and its ability to meet capital needs later in 2025. The company's stock is listed on The Nasdaq Capital Market under the symbol 'PCSA.'

Form Type: 424B4

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004111

Filing Summary: Processa Pharmaceuticals, Inc. is conducting a public offering of 1,030,972 shares of common stock along with various warrants including 7,019,700 Pre-Funded Warrants and Series A and B Warrants. The combined purchase price is set at $0.615 per share for institutional investors and $0.7975 for certain insiders. The Series A warrants will expire five years after stockholder approval, while Series B warrants expire in eighteen months. The offering includes provisions for investors whose ownership would exceed 4.99% post-offering, allowing them to purchase Pre-Funded Warrants instead of shares. The pricing structure for the warrants is detailed, and there are no minimum requirements for the offering, causing potential risk for investors. Currently, the company's stock is traded on The Nasdaq Capital Market under the symbol 'PCSA,' with the last reported price of $0.68 per share. The document outlines where investors can find additional information and emphasizes the risks involved in investing in the offerings. Delivery of securities is expected around January 29, 2025.

Form Type: CORRESP

Filing Date: 2025-01-27

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003730

Filing Summary: Processa Pharmaceuticals, Inc. submitted a correspondence to the United States Securities and Exchange Commission seeking the acceleration of effectiveness for their Registration Statement on Form S-1 (Registration No. 333-283986) to 4:30 P.M. Eastern time on January 27, 2025. The request signifies an important step towards the company’s initial public offering (IPO). The correspondence includes a directive for the SEC to notify Mr. Michael Kirwan of Foley & Lardner LLP regarding the effectiveness of the registration statement.

Form Type: CORRESP

Filing Date: 2025-01-27

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003731

Filing Summary: Processa Pharmaceuticals, Inc. is requesting the U.S. Securities and Exchange Commission to take action to cause their Registration Statement on Form S-1 to become effective on January 27, 2025. The request is made by A.G.P./Alliance Global Partners, acting as Sole Placement Agent. This action is part of their initial public offering (IPO) process, which will allow for the distribution of the Preliminary Prospectus to prospective dealers and investors. The Placement Agent confirms compliance with relevant rules under the Securities Exchange Act of 1934.

Form Type: S-1/A

Filing Date: 2025-01-27

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225003720

Filing Summary: Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, filed its amendment to Form S-1 registration statement to register up to 11,764,706 shares of common stock along with pre-funded warrants and series A and B warrants. The offering aims to provide better oncology treatment options through next-generation chemotherapy approaches that enhance the efficacy and safety profiles of existing cancer drugs. The company is leveraging its Regulatory Science Approach, informed by the FDA’s Project Optimus Initiative, to improve outcomes for cancer patients. The public offering price is set at an assumed $0.68 per share, and the offering is expected to commence as soon as the registration statement is effective. The offering will terminate on March 11, 2025, unless the company decides to terminate it earlier. A.G.P./Alliance Global Partners has been engaged as the exclusive placement agent, and the company plans to utilize the proceeds for its drug development pipeline, focusing initially on enhancing existing FDA-approved oncology drugs.

Form Type: CORRESP

Filing Date: 2025-01-17

Corporate Action: Ipo

Type: New

Accession Number: 000149315225002809

Filing Summary: Processa Pharmaceuticals, Inc. is requesting the Securities and Exchange Commission to take action to make its Registration Statement on Form S-1 effective on January 22, 2025. The request is made by A.G.P./ALLIANCE GLOBAL PARTNERS, acting as the Sole Placement Agent. They inform the SEC that copies of the Preliminary Prospectus dated January 16, 2025, will be distributed to ensure adequate reach to prospective dealers and investors. A.G.P. confirms its compliance with Rule 15c2-8 under the Securities Exchange Act of 1934 regarding delivery requirements.

Form Type: S-1/A

Filing Date: 2025-01-16

Corporate Action: Ipo

Type: New

Accession Number: 000149315225002455

Filing Summary: Processa Pharmaceuticals, Inc. is making a public offering of its securities by registering up to 9,400,705 shares of common stock, along with associated Pre-Funded and Common Warrants, for an initial price of $0.851 per share. The offering aims to commence as soon as practicable after the registration statement becomes effective. The placement agent, A.G.P./Alliance Global Partners, will receive a fee of 6.5% of the gross proceeds from sales, with reduced fees applicable to certain investors. This move is part of their strategy to expand their clinical-stage biopharmaceutical development focused on oncology drugs. The company utilizes an approach rooted in regulatory science, particularly the FDA's Project Optimus Oncology initiative, to improve existing approved cancer treatments. They focus on three proprietary small molecule oncology drugs that demonstrate improved efficacy and safety compared to existing therapies. Notably, their NGC treatments have shown promising pharmacological activity and aim to enhance the therapeutic profiles of currently marketed chemotherapy drugs while minimizing side effects. The closing date for this offering is expected to be around March 11, 2025.